Aldosterone synthase inhibitors in cardiovascular and renal diseases.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ndt/gft402PMID 24493871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aldosterone synthase inhibition in humans.

  2013cited by this paper
• Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism

  2013cited by this paper
• Aldosterone Modulates Endothelial Permeability and Endothelial Nitric Oxide Synthase Activity by Rearrangement of the Actin Cytoskeleton

  2013cited by this paper
• Aldosterone synthase inhibitors: targeting chronic kidney disease and diabetic nephropathy.

  2013cited by this paper
• Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

  2013cited by this paper
• Aldosterone and cardiovascular disease: the heart of the matter.

  2013cited by this paper
• Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension

  2013cited by this paper
• Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.

  2013cited by this paper
• Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation.

  2013cited by this paper
• Neovascularization Is Attenuated With Aldosterone Synthase Inhibition in Rats With Retinopathy

  2012cited by this paper
• The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study

  2012cited by this paper
• 3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2

  2012cited by this paper
• Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases.

  2012cited by this paper
• Extrarenal effects of aldosterone

  2012cited by this paper
• Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.

  2012cited by this paper
• Aldosterone-induced fibrosis in the kidney: questions and controversies.

  2011cited by this paper
• Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.

  2011influential reference
• GPR30 Expression Is Required for the Mineralocorticoid Receptor–Independent Rapid Vascular Effects of Aldosterone

  2011cited by this paper
• Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.

  2011cited by this paper
• Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches

  2011cited by this paper
• Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial

  2011cited by this paper
• Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism

  2010cited by this paper
• FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice

  2010cited by this paper
• Pharmacodynamic and Pharmacokinetic Characterization of the Aldosterone Synthase Inhibitor FAD286 in Two Rodent Models of Hyperaldosteronism: Comparison with the 11β-Hydroxylase Inhibitor Metyrapone

  2010cited by this paper
• Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria

  2010cited by this paper
• HORMONAL AND ELECTROLYTE RESPONSES TO THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN SODIUM DEPLETED HEALTHY SUBJECTS

  2010cited by this paper
• Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

  2009cited by this paper
• Reconsidering the Roles of the Mineralocorticoid Receptor

  2009cited by this paper
• Aldosterone Stimulates Elastogenesis in Cardiac Fibroblasts via Mineralocorticoid Receptor-independent Action Involving the Consecutive Activation of Gα13, c-Src, the Insulin-like Growth Factor-I Receptor, and Phosphatidylinositol 3-Kinase/Akt*

  2009cited by this paper
• Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.

  2008cited by this paper
• Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?

  2008cited by this paper
• Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats.

  2008cited by this paper
• Aldosterone and the vascular system.

  2008influential reference
• Heterogeneity of Aldosterone-Producing Adenomas Revealed by a Whole Transcriptome Analysis

  2007cited by this paper
• Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter.

  2007cited by this paper
• Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?

  2006cited by this paper
• Aldosterone and end-organ damage.

  2005influential reference
• Aldosterone Biosynthesis, Regulation, and Classical Mechanism of Action

  2005cited by this paper
• Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions.

  2005cited by this paper
• Aldosterone and end-organ damage

  2005cited by this paper
• Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage

  2005cited by this paper

• New drug therapies for hypertension.

  2026cites this paper
• Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension-Reply.

  2025cites this paper
• Efficacy and safety of aldosterone synthase inhibitors for uncontrolled hypertension: a meta-analysis of randomized controlled trials and systematic review

  2025cites this paper
• Aldosterone: From Essential Tubular Regulator to Pathological Driver—Physiology, Disease, and Therapeutic Advances

  2025cites this paper
• Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible?

  2025cites this paper
• The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin–Angiotensin–Aldosterone System Therapy Limitations: A Narrative Review

  2025cites this paper
• Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosing.

  2025cites this paper
• Safety and efficacy of sodium-glucose co-transporter-2 inhibitors and aldosterone inhibitors combinations in chronic kidney disease: A systematic review and meta-analysis.

  2025cites this paper
• New Therapies for the Management of Chronic Kidney Disease

  2025cites this paper
• Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors - impact on enzyme kinetics of steroidogenesis.

  2025cites this paper
• Aldosterone Synthase Inhibitor BI 690517: Specificity for Mineralocorticoid Receptor.

  2025cites this paper
• Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers

  2025cites this paper
• Association of combined −344T/C and K173R polymorphisms in aldosterone synthase gene with type 2 diabetes mellitus in the Moroccan population

  2024cites this paper
• The Effects of Aldosterone on Hypertension-Associated Kidney Injury in a Tg-hAS Mouse Model

  2024cites this paper
• Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models

  2024cites this paper
• Effects of CYP11B2 gene polymorphisms on adrenocorticotropic hormone and angiotensin II in type 2 diabetes patients with hypertension

  2024cites this paper
• Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.

  2024cites this paper
• Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial

  2024cites this paper
• Aldosterone: Renal Action and Physiological Effects.

  2023cites this paper
• Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

  2023cites this paper
• Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease

  2023cites this paper
• The impact of different diuretics on regression of myocardial reperfusion injury in spontaneously hypertensive rats

  2022cites this paper
• Association of the Aldosterone Synthase Gene (CYP11B2) Polymorphic Locus rs1799998, c.–344C>T with the Development of Pulmonary Sarcoidosis

  2021cites this paper
• Aldosterone Synthase Structure With Cushing Disease Drug LCI699 Highlights Avenues for Selective CYP11B Drug Design

  2021cites this paper
• Curcumin Suppresses Aldosterone-Induced CRP Generation in Rat Vascular Smooth Muscle Cells via Interfering with the ROS-ERK1/2 Signaling Pathway

  2020cites this paper
• THE ROLE OF ALDOSTERONE INHIBITORS ON CARDIAC ISCHEMIA/REPERFUSION INJURY.

  2020cites this paper
• New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

  2019cites this paper
• Inhibitors of Aldosterone Synthase.

  2019cites this paper
• Obesity, kidney dysfunction and hypertension: mechanistic links

  2019cites this paper
• Investigating a novel pathway for hypertension and pharmacologic response involving the dicarboxylic acid, hexadecanedioate

  2019cites this paper
• Caloric restriction improves glucose homeostasis, yet increases cardiometabolic risk in caveolin-1-deficient mice.

  2018cites this paper
• Eplerenone inhibits aldosterone-induced CRP generation in rat vascular smooth muscle cells by regulating the MR-ROS-ERK1/2 signal pathway

  2017cites this paper
• 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures.

  2017cites this paper
• Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease

  2016cites this paper
• Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates

  2016cites this paper
• Metabolism of Oral Turinabol by Human Steroid Hormone–Synthesizing Cytochrome P450 Enzymes

  2016cites this paper
• The potential of targeting CYP11B

  2016cites this paper
• Discovery of Potential Inhibitors of Aldosterone Synthase from Chinese Herbs Using Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Studies

  2016cites this paper
• Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats

  2016cites this paper
• Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats

  2016cites this paper
• Prevention of cardiac remodeling after experimental myocardial infarction. Role of the angiotensin II type 2 receptor stimulation and modulation of MMP/TIMP axis

  2016cites this paper
• Mega clinical trials which have shaped the RAS intervention clinical practice

  2016cites this paper
• An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

  2016cites this paper
• Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

  2016cites this paper
• ZSF1 rat: a model of chronic cardiac and renal diseases in the context of metabolic syndrome. Characterization with anti-oxidant, mineralocorticoid receptor antagonist and aldosterone synthase inhibitor

  2015cites this paper
• ROMO1 links oxidative stress to mitochondrial integrity

  2015cites this paper
• Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

  2015cites this paper
• Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

  2015cites this paper
• Ginsenoside Rg1 reduces aldosterone-induced autophagy via the AMPK/mTOR pathway in NRK-52E cells.

  2015cites this paper
• Critical insights into the beneficial and protective actions of the kallikrein-kinin system.

  2015cites this paper
• Metabolism of oral-turinabol by human steroid hormone-synthesizing cytochromes P450 •

  2015cites this paper
• Ginsenoside Rg 1 reduces aldosterone-induced autophagy via the AMPK / mTOR pathway in NRK-52 E cells

  2015cites this paper
• The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient

  2015cites this paper
• Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials

  2015cites this paper
• Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.

  2015cites this paper
• EndogenousCardiotonicSteroidsinKidneyFailure: A Review and an Hypothesis

  2015cites this paper
• The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes

  2014cites this paper
• On the Pleotropic Actions of Mineralocorticoids

  2014cites this paper
• TWEAK and the progression of renal disease: clinical translation.

  2014cites this paper
• Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells.

  2014cites this paper
• Mineralocorticoid and SGK1-Sensitive Inflammation and Tissue Fibrosis

  2014cites this paper
• Genetic, Molecular and Clinical Determinants for the Involvement of Aldosterone and Its Receptors in Major Depression

  2014cites this paper
• Interfering with mineralocorticoid receptor activation: the past, present, and future

  2014cites this paper